scholarly journals Association between APOC3 polymorphisms and non-alcoholic fatty liver disease risk: a meta-analysis

2020 ◽  
Vol 20 (4) ◽  
pp. 1800-8
Author(s):  
Jun Wang ◽  
Chuncui Ye ◽  
Sujuan Fei
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Disease Risk ◽  
Meta Analysis ◽  
Group Analysis ◽  
Alcoholic Fatty Liver ◽  
Apolipoprotein C3 ◽  
Apoc3 Gene ◽  
Alcoholic Fatty Liver Disease

Background and Aim: The apolipoprotein C3 (APOC3) polymorphism has been reported to predispose to non-alcoholic fatty liver disease (NAFLD). However, the results remain inconclusive. This meta-analysis aimed to provide insights into the association between APOC3 polymorphisms and NAFLD risk. Methods: Studies with terms “NALFD” and “APOC3” were retrieved from PubMed, Web of Science, CNKI and Wan- fang databases up to August 1, 2019. Pooled odds ratio (OR) and 95% confidence interval (95% CI) for the association of APOC3 polymorphisms and NAFLD risk were calculated using fixed and random-effects models. Results: A total of twelve studies from eleven articles were included. Of them, eight studies (1750 cases and 2181 controls) reported the strong association of variant rs2854116 with NAFLD and six studies (1523 cases and 1568 controls) found the association of rs2854117 polymorphism with NAFLD. Overall, a statistically significant association between rs2854116 pol- ymorphism of APOC3 gene and NAFLD risk was found only under dominant model. However, association of rs2854117 polymorphism with NAFLD risk was not detected under all four genetic models. In sub-group analysis of NAFLD subjects based on country, no association among them in China was detected. Besides, four studies analyze the association between the two polymorphisms and clinical characteristics in all subjects or NAFLD patients, and we also failed detect any associa- tion between the wild carriers and variant carriers. Conclusion: The meta-analyses suggests that the rs2854116 polymorphism but not rs2854117 polymorphism in APOC3 gene might be a risk factor for NAFLD among Asians. That is, individuals with CT+CC genotype have higher risk of devel- oping NAFLD. However, studies with sufficient sample size are needed for the further validation. Keywords: Apolipoprotein C3; polymorphism; non-alcoholic fatty liver disease; meta-analysis.

scholarly journals Association of apolipoprotein C3 polymorphisms with non-alcoholic fatty liver disease: an updated meta-analysis

2020 ◽  
Author(s):  
Yu-Kang Chang ◽  
Kuan-Chun Hsueh ◽  
Chia-Hung Liu ◽  
Yen-Li Lo ◽  
Yang-Sheng Lin ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Promoter Region ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Caucasian Population ◽  
Alcoholic Fatty Liver ◽  
Apolipoprotein C3 ◽  
Functional Polymorphisms ◽  
Alcoholic Fatty Liver Disease

Abstract Background The relationships between gene polymorphisms of apolipoprotein C3 (APOC3) and risk of non-alcoholic fatty liver disease (NAFLD) have been investigated, however, their findings were inconclusive. The aim of this meta-analysis is to evaluate the effects of APOC3 promoter region polymorphisms (-455T/C and − 482C/T) on the susceptibility to NAFLD. Methods A comprehensive literature search was carried out with electronic databases including MEDLINE, EMBASE, Web of Science, and Google Scholar to identify eligible studies up to June 2019. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the combined effect sizes. The level of heterogeneity, sensitivity, subgroup, and publication bias analyses were subsequently conducted. Results This meta-analysis included seven studies, containing 1,318 NAFLD cases and 1,691 controls fulfilling the inclusion and exclusion criteria. The pooled analysis showed significant associations between APOC3 -455T/C polymorphism and risk of NAFLD in allelic model (OR = 1.33) and recessive model (OR = 1.67), but not in the dominant model. When stratified by ethnicity, the polymorphism − 455T/C was found to be significantly associated with risk of NAFLD in the Caucasian population, but not in the Asian population. No association was evident between the polymorphism − 482C/T and risk of NAFLD. Conclusions Our findings suggest that APOC3 promoter region polymorphism − 455T/C may associate with risk of NAFLD in Caucasian population. Further studies with other functional polymorphisms are helpful to discover the effects of APOC3 gene on the development of NAFLD.

scholarly journals A PRISMA-compliant meta-analysis of apolipoprotein C3 polymorphisms and non-alcoholic fatty liver disease

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Bing-Feng Chen ◽  
Yeuh Chien ◽  
Pin-Hsing Tsai ◽  
Pang-Chung Perng ◽  
Yi-Ping Yang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Alcoholic Fatty Liver ◽  
Apolipoprotein C3 ◽  
Alcoholic Fatty Liver Disease

Adiponectin polymorphisms and non-alcoholic fatty liver disease risk: A meta-analysis

2014 ◽  
Vol 29 (7) ◽  
pp. 1396-1405 ◽  
Author(s):  
Jun Wang ◽  
Xu-Feng Guo ◽  
Shi-Jie Yu ◽  
Jia Song ◽  
Ji-Xiang Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Disease Risk ◽  
Meta Analysis ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 10 (11) ◽  
pp. 2415
Author(s):  
Yasaman Vali ◽  
Jenny Lee ◽  
Jérôme Boursier ◽  
René Spijker ◽  
Joanne Verheij ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Advanced Fibrosis ◽  
Alcoholic Fatty Liver ◽  
Multiple Thresholds ◽  
Meta Analyses ◽  
Alcoholic Fatty Liver Disease

(1) Background: FibroTest™ is a multi-marker panel, suggested by guidelines as one of the surrogate markers with acceptable performance for detecting fibrosis in patients with non-alcoholic fatty liver disease (NAFLD). A number of studies evaluating this test have been published after publication of the guidelines. This study aims to produce summary estimates of FibroTest™ diagnostic accuracy. (2) Methods: Five databases were searched for studies that evaluated FibroTest™ against liver biopsy as the reference standard in NAFLD patients. Two authors independently screened the references, extracted data, and assessed the quality of included studies. Meta-analyses of the accuracy in detecting different levels of fibrosis were performed using the bivariate random-effects model and the linear mixed-effects multiple thresholds model. (3) Results: From ten included studies, seven were eligible for inclusion in our meta-analysis. Five studies were included in the meta-analysis of FibroTest™ in detecting advanced fibrosis and five in significant fibrosis, resulting in an AUC of 0.77 for both target conditions. The meta-analysis of three studies resulted in an AUC of 0.69 in detecting any fibrosis, while analysis of three other studies showed higher accuracy in cirrhosis (AUC: 0.92). (4) Conclusions: Our meta-analysis showed acceptable performance (AUC > 0.80) of FibroTest™ only in detecting cirrhosis. We observed more limited performance of the test in detecting significant and advanced fibrosis in NAFLD patients. Further primary studies with high methodological quality are required to validate the reliability of the test for detecting different fibrosis levels and to compare the performance of the test in different settings.

Sign in / Sign up

Export Citation Format

Share Document